BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 32429651)

  • 1. Image analysis discloses differences in nuclear parameters between ERG+ and ERG- prostatic carcinomas.
    Okoń K; Dyduch G; Białas MB; Milian-Ciesielska K; Szpor J; Leszczyńska I; Tyrak K; Szopiński T; Chłosta P
    Pol J Pathol; 2020; 71(1):20-29. PubMed ID: 32429651
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Frequency and transcript variant analysis of gene fusions between TMPRSS2 and ETS transcription factor genes in prostate cancer].
    Dai MJ; Chen LL; Zheng YB; Chen W; Tao ZH; Weng ZL; Wu XL; Li CD; Chen ZG; Chen XD; Shi SB
    Zhonghua Yi Xue Za Zhi; 2008 Mar; 88(10):669-73. PubMed ID: 18642766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer.
    Hermans KG; van Marion R; van Dekken H; Jenster G; van Weerden WM; Trapman J
    Cancer Res; 2006 Nov; 66(22):10658-63. PubMed ID: 17108102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming.
    Iljin K; Wolf M; Edgren H; Gupta S; Kilpinen S; Skotheim RI; Peltola M; Smit F; Verhaegh G; Schalken J; Nees M; Kallioniemi O
    Cancer Res; 2006 Nov; 66(21):10242-6. PubMed ID: 17079440
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retention of Interstitial Genes between
    Murphy SJ; Kosari F; Karnes RJ; Nasir A; Johnson SH; Gaitatzes AG; Smadbeck JB; Rangel LJ; Vasmatzis G; Cheville JC
    Cancer Res; 2017 Nov; 77(22):6157-6167. PubMed ID: 29127096
    [No Abstract]   [Full Text] [Related]  

  • 6. βIII-tubulin overexpression is an independent predictor of prostate cancer progression tightly linked to ERG fusion status and PTEN deletion.
    Tsourlakis MC; Weigand P; Grupp K; Kluth M; Steurer S; Schlomm T; Graefen M; Huland H; Salomon G; Steuber T; Wilczak W; Sirma H; Simon R; Sauter G; Minner S; Quaas A
    Am J Pathol; 2014 Mar; 184(3):609-17. PubMed ID: 24378408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transcriptomes of Prostate Cancer with TMPRSS2:ERG and Other ETS Fusions.
    Stopsack KH; Su XA; Vaselkiv JB; Graff RE; Ebot EM; Pettersson A; Lis RT; Fiorentino M; Loda M; Penney KL; Lotan TL; Mucci LA
    Mol Cancer Res; 2023 Jan; 21(1):14-23. PubMed ID: 36125519
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of SLC45A3 protein (prostein) expression in prostate cancer is associated with SLC45A3-ERG gene rearrangement and an unfavorable clinical course.
    Perner S; Rupp NJ; Braun M; Rubin MA; Moch H; Dietel M; Wernert N; Jung K; Stephan C; Kristiansen G
    Int J Cancer; 2013 Feb; 132(4):807-12. PubMed ID: 22821757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The expression profile and heterogeneity analysis of ERG in 633 consecutive prostate cancers from a single center.
    Nie L; Pan X; Zhang M; Yin X; Gong J; Chen X; Xu M; Zhou Q; Chen N
    Prostate; 2019 Jun; 79(8):819-825. PubMed ID: 30900303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Significance of the TMPRSS2:ERG gene fusion in prostate cancer.
    Wang Z; Wang Y; Zhang J; Hu Q; Zhi F; Zhang S; Mao D; Zhang Y; Liang H
    Mol Med Rep; 2017 Oct; 16(4):5450-5458. PubMed ID: 28849022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate cancer: Stuck in the middle: interstitial genes in TMPRSS2-ERG fusion.
    Stone L
    Nat Rev Urol; 2018 Jan; 15(1):3. PubMed ID: 29205202
    [No Abstract]   [Full Text] [Related]  

  • 12. Correlation of ERG expression and DNA methylation biomarkers with adverse clinicopathologic features of prostate cancer.
    Kron K; Liu L; Trudel D; Pethe V; Trachtenberg J; Fleshner N; Bapat B; van der Kwast T
    Clin Cancer Res; 2012 May; 18(10):2896-904. PubMed ID: 22452941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Truncated ERG proteins affect the aggressiveness of prostate cancer.
    Wu F; Ding S; Lu J
    Med Hypotheses; 2013 Apr; 80(4):490-3. PubMed ID: 23357671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prognostic and predictive value of TMPRSS2-ERG gene fusion and ERG protein expression in prostate cancer biopsies.
    Berg KD
    Dan Med J; 2016 Dec; 63(12):. PubMed ID: 27910803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relative 8q gain predicts disease-specific survival irrespective of the TMPRSS2-ERG fusion status in diagnostic biopsies of prostate cancer.
    Barros-Silva JD; Ribeiro FR; Rodrigues A; Cruz R; Martins AT; Jerónimo C; Henrique R; Teixeira MR
    Genes Chromosomes Cancer; 2011 Aug; 50(8):662-71. PubMed ID: 21584900
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Morphological features of TMPRSS2-ERG gene fusion prostate cancer.
    Mosquera JM; Perner S; Demichelis F; Kim R; Hofer MD; Mertz KD; Paris PL; Simko J; Collins C; Bismar TA; Chinnaiyan AM; Rubin MA
    J Pathol; 2007 May; 212(1):91-101. PubMed ID: 17385188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apurinic/apyrimidinic endonuclease 1 (APE1/Ref-1) overexpression is an independent prognostic marker in prostate cancer without TMPRSS2:ERG fusion.
    Juhnke M; Heumann A; Chirico V; Höflmayer D; Menz A; Hinsch A; Hube-Magg C; Kluth M; Lang DS; Möller-Koop C; Sauter G; Simon R; Beyer B; Pompe R; Thederan I; Schlomm T; Luebke AM
    Mol Carcinog; 2017 Sep; 56(9):2135-2145. PubMed ID: 28467610
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TMPRSS2:ETS fusions and clinicopathologic characteristics of prostate cancer patients from Eastern China.
    Dong J; Xiao L; Sheng L; Xu J; Sun ZQ
    Asian Pac J Cancer Prev; 2014; 15(7):3099-103. PubMed ID: 24815454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TMPRSS2/ERG fusion gene expression alters chemo- and radio-responsiveness in cell culture models of androgen independent prostate cancer.
    Swanson TA; Krueger SA; Galoforo S; Thibodeau BJ; Martinez AA; Wilson GD; Marples B
    Prostate; 2011 Oct; 71(14):1548-58. PubMed ID: 21394739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nuclear C-MYC expression level is associated with disease progression and potentially predictive of two year overall survival in prostate cancer.
    Zeng W; Sun H; Meng F; Liu Z; Xiong J; Zhou S; Li F; Hu J; Hu Z; Liu Z
    Int J Clin Exp Pathol; 2015; 8(2):1878-88. PubMed ID: 25973080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.